
|Videos|July 13, 2022
Lenalidomide plus Tafasitamab for R/R DLBCL: The L-MIND Trial
Author(s)Grzegorz S. Nowakowski, MD
An explanation of the design, efficacy, and adverse events of L-MIND, a trial investigating a combination treatment for R/R DLBCL.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
3
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
4
FDA Oncology Update January 2026: New Horizons in Precision Medicine
5



















